{"id":265484,"date":"2026-09-23T16:51:48","date_gmt":"2026-09-23T11:21:48","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=265484"},"modified":"2026-09-23T16:51:48","modified_gmt":"2026-09-23T11:21:48","slug":"bafna-pharmaceuticals-best-stock-in-its-sector","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-best-stock-in-its-sector\/","title":{"rendered":"Is Bafna Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers"},"content":{"rendered":"

Bafna Pharmaceuticals CMP Rs 336 (23 Sep 2026). Market cap Rs 794 Cr. ROE 11.54%. P\/E 101.98x versus Industry P\/E 51.81x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Bafna Pharmaceuticals is one of the names investors compare when screening the Healthcare sector, built on a 11.54% return on equity and a P\/E of 101.98x against an Industry P\/E of 51.81x. Whether Bafna Pharmaceuticals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.<\/p>\n<\/p><\/div>\n

Is Bafna Pharmaceuticals<\/a> the best stock in its sector? The stock trades on the NSE at Rs 336 as of 23 September 2026, within its 52-week range of Rs 94.77 to Rs 336.50. Bafna Pharmaceuticals Ltd manufactures pharmaceutical formulations.<\/p>\n

Bafna Pharmaceuticals sits in the Healthcare sector, and its 11.54% ROE and 101.98x P\/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P\/E benchmark.<\/p>\n

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n